HP is helping produce drugs for Center of Disease Control (CDC) for its pilot program to tackle the superbug issue that affects roughly 23,000 people in the U.S. The idea of participation came due to HP’s prowess in print technology. HP’s Biohacker technology will be working on this pilot program to 3D print drugs that would prevent the antimicrobial resistant strains from spreading.
3D printing technology has been on a fast track in the last two years. There have been innovations in this space that include drug research and development to augment the healthcare industry which has been always under stress to produce more and more drugs year after year.
There has been a decline in the expected lifespan of patients and the overall health statistics due to the antibiotic resistance superbug issue which could escalate into a very big problem with increasing reliance on drugs.
CDC will use HP’s Bioprinters in four regions across the U.S. in the AR Lab Network to work on developing and testing antimicrobial susceptibility for newer drugs. Jean Patel, Science Team Lead, Antibiotic Resistance Coordination and Strategy Unit said in a statement: “We hope this pilot will help ensure our newest drugs last longer and put gold-standard lab results in healthcare providers’ hands faster.”